Overview

Thalidomide in Treating Patients With Gynecologic Sarcomas

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of gynecologic sarcomas by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent gynecologic sarcomas.
Phase:
Phase 2
Details
Lead Sponsor:
New York University Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
Thalidomide